[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infantile-hemangioma-ih\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infantile-hemangioma-ih":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644001","risk-stratification-and-treatment-decisions-in-infantile-hemangioma-with-minimal-or-arrested-growth-100644001",false,"NCT07669545","Risk Stratification and Treatment Decisions in Infantile Hemangioma With Minimal or Arrested Growth","Infantile Hemangioma With Minimal or Arrested Growth Versus Typical Infantile Hemangioma: A Prospective Cohort Study of Risk Stratification and Treatment Decision-Making","IH-MAGRST","Inclusion Criteria:\n\n* Infants clinically diagnosed with infantile hemangioma, including minimal or arrested growth infantile hemangioma and classic infantile hemangioma.\n* Participants undergoing their initial specialist evaluation at the study center.\n* Age at baseline: from birth to 24 months.\n* Sufficient clinical information available for baseline assessment, including lesion location, morphology, size, number of lesions, complications, and treatment recommendation.\n* Parents or legal guardians are able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with vascular anomalies other than infantile hemangioma, including vascular malformations, congenital hemangioma, kaposiform hemangioendothelioma, pyogenic granuloma, or other vascular tumors.\n* Patients with insufficient clinical information to determine the infantile hemangioma subtype, AAP risk category, Hemangioma Severity Scale score, or baseline treatment recommendation.\n* Patients who have received systemic pharmacologic treatment, procedural treatment, laser therapy, or surgical treatment for infantile hemangioma before the baseline specialist evaluation.\n* Patients with severe comorbidities or unstable medical conditions that may interfere with clinical assessment or follow-up.\n* Parents or legal guardians who decline participation or are unable to provide informed consent.","ALL","0 Months","12 Months",{"count":21,"type":22},150,"ESTIMATED","OBSERVATIONAL","Infantile hemangioma with minimal or arrested growth (IH-MAG) is a subtype of infantile hemangioma that shows little or no obvious growth during infancy. Although these lesions may appear less active than classic infantile hemangiomas, some may still be associated with ulceration, functional risk, permanent disfigurement, or structural anomalies.\n\nThis prospective observational cohort study will compare infants with IH-MAG and infants with classic infantile hemangioma at their first specialist evaluation. Each participant will undergo routine clinical assessment, standardized photography, risk classification according to the 2019 American Academy of Pediatrics guideline, and Hemangioma Severity Scale scoring. The main outcome is the initial management recommendation after specialist assessment, categorized as active management or treatment versus observation. The study will not assign any treatment. All management recommendations will be made by clinicians according to routine clinical practice and guideline-based assessment.",[26],"Infantile Hemangioma (IH)",[28,29],"Infantile Hemangioma With Minimal or Arrested Growth","infantile hemangioma","NOT_YET_RECRUITING","2026-07-01",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":22},"2026-06-20",{"date":38,"type":22},"2028-03-30",{"name":40,"class":41},"West China Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":69,"locationsCount":42},"100644176","phase-4-abrupt-discontinuation-versus-gradual-tapering-of-propranolol-in-infantile-hemangioma-100644176","NCT07665177","Abrupt Discontinuation Versus Gradual Tapering of Propranolol in Infantile Hemangioma","Rebound Growth After Abrupt Discontinuation Versus Gradual Tapering of Propranolol in Infantile Hemangioma: A Multicenter Randomized Noninferiority Trial","PROIHSTOP","Inclusion Criteria:\n\n1. Children with a clinical diagnosis of infantile hemangioma.\n2. Complete pretreatment clinical documentation is available, including clinical photographs and\u002For ultrasound findings.\n3. The child has received oral propranolol for at least 6 months.\n4. The infantile hemangioma meets the predefined criteria for propranolol discontinuation, defined as complete or near-complete clinical regression, no obvious residual blood flow on ultrasound, and stable maximal regression for 3 months.\n5. Written informed consent is provided by a parent or legal guardian.\n6. The parent or legal guardian is able and willing to complete the scheduled follow-up assessments.\n\nExclusion Criteria:\n\n1. Airway or hepatic infantile hemangiomas, or other high-risk lesions for which rebound growth could rapidly compromise life or vital organ function.\n2. Use of propranolol for arrhythmia, hypertension, or another cardiovascular indication.\n3. A history of rebound growth after prior discontinuation of propranolol.\n4. Laser therapy, sclerotherapy, surgery, systemic corticosteroids, or other systemic treatment within 3 months before randomization.\n5. Severe cardiac, respiratory, hepatic, renal, metabolic, or other systemic disease that may affect participant safety or study assessment.\n6. Inability to complete standardized photography, ultrasound assessment, or scheduled follow-up.","6 Months","60 Months",{"count":54,"type":22},110,"INTERVENTIONAL",[57],"PHASE4","Infantile hemangioma is the most common benign vascular tumor in infancy. Oral propranolol is the first-line systemic treatment for infantile hemangiomas requiring therapy. Although most patients respond well to propranolol, rebound growth may occur after treatment discontinuation, and some patients may require restarting propranolol or receiving additional treatment. In clinical practice, propranolol may be discontinued abruptly after the lesion meets discontinuation criteria, or gradually tapered over several weeks before complete discontinuation. However, high-quality randomized evidence comparing these two discontinuation strategies remains limited.\n\nThis multicenter randomized noninferiority trial aims to compare the risk of rebound growth after abrupt discontinuation versus gradual tapering of propranolol in patients with infantile hemangioma who have received oral propranolol for at least 6 months and meet predefined discontinuation criteria.",[26],[61,62,63],"Infantile hemangioma","Propranolol","rebound growth","2026-06-18",{"date":66,"type":34},"2026-06-24",{"date":31,"type":22},{"date":38,"type":22},{"name":40,"class":41}]